These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 20425441)

  • 21. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.
    Melchert M; Kale V; List A
    Curr Opin Hematol; 2007 Mar; 14(2):123-9. PubMed ID: 17255789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted therapies in myelodysplastic syndrome.
    Melchert M; List A
    Semin Hematol; 2008 Jan; 45(1):31-8. PubMed ID: 18179967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aberrant expression of the microRNA cluster in 14q32 is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment.
    Krejčík Z; Beličková M; Hruštincová A; Kléma J; Zemanová Z; Michalová K; Čermák J; Jonášová A; Dostálová Merkerová M
    Cancer Genet; 2015 Apr; 208(4):156-61. PubMed ID: 25883014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The evolving role of lenalidomide in the treatment of hematologic malignancies.
    Kastritis E; Dimopoulos MA
    Expert Opin Pharmacother; 2007 Mar; 8(4):497-509. PubMed ID: 17309344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on the pharmacotherapy for myelodysplastic syndromes.
    Duong VH; Komrokji RS; List AF
    Expert Opin Pharmacother; 2014 Sep; 15(13):1811-25. PubMed ID: 25080144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
    Talati C; Sallman D; List A
    Semin Hematol; 2017 Jul; 54(3):159-166. PubMed ID: 28958290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunomodulatory drugs in myelodysplastic syndromes.
    Galili N; Raza A
    Expert Opin Investig Drugs; 2006 Jul; 15(7):805-13. PubMed ID: 16787143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current treatment options and strategies for myelodysplastic syndromes.
    Srinivasan S; Schiffer CA
    Expert Opin Pharmacother; 2008 Jul; 9(10):1667-78. PubMed ID: 18570600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lenalidomide for treatment of myelodysplastic syndromes.
    Komrokji RS; List AF
    Curr Pharm Des; 2012; 18(22):3198-203. PubMed ID: 22571699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
    Jonasova A; Bokorova R; Polak J; Vostry M; Kostecka A; Hajkova H; Neuwirtova R; Siskova M; Sponerova D; Cermak J; Mikulenkova D; Cervinek L; Brezinova J; Michalova K; Fuchs O
    Eur J Haematol; 2015 Jul; 95(1):27-34. PubMed ID: 25284710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.
    Ball B; Zeidan A; Gore SD; Prebet T
    Leuk Lymphoma; 2017 May; 58(5):1022-1036. PubMed ID: 27654579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunomodulatory therapy for myelodysplastic syndromes.
    Sokol L; List AF
    Int J Hematol; 2007 Nov; 86(4):301-5. PubMed ID: 18055335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.
    Mittelman M; Filanovsky K; Ofran Y; Rosenbaum H; Raanani P; Braester A; Goldschmidt N; Kirgner I; Herishanu Y; Perri C; Ellis M; Oster HS;
    Ann Hematol; 2016 Oct; 95(11):1811-8. PubMed ID: 27546027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?
    DeZern AE
    Hematology Am Soc Hematol Educ Program; 2015; 2015():308-16. PubMed ID: 26637738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?
    Komrokji RS; Lancet JE; List AF
    Curr Hematol Malig Rep; 2010 Jan; 5(1):9-14. PubMed ID: 20425391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lenalidomide as a novel treatment of acute myeloid leukemia.
    Chen Y; Borthakur G
    Expert Opin Investig Drugs; 2013 Mar; 22(3):389-97. PubMed ID: 23316859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
    Fuchs O
    Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):51-78. PubMed ID: 29788898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond.
    Guirguis AA; Ebert BL
    Curr Opin Cell Biol; 2015 Dec; 37():61-7. PubMed ID: 26512454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Angiogenesis in patients with hematologic malignancies].
    Mesters RM; Padró T; Steins M; Bieker R; Retzlaff S; Kessler T; Kienast J; Berdel WE
    Onkologie; 2001 Sep; 24 Suppl 5():75-80. PubMed ID: 11600818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical experience with antiangiogenic therapy in leukemia.
    Wellbrock J; Fiedler W
    Curr Cancer Drug Targets; 2011 Nov; 11(9):1053-68. PubMed ID: 21999626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.